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Introduction: Current practice in the delivery of caloric intake (DCI) in patients with severe acute kidney injury
(AKI) receiving renal replacement therapy (RRT) is unknown. We aimed to describe calorie administration in patients
enrolled in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study and
to assess the association between DCI and clinical outcomes.
Methods: We performed a secondary analysis in 1456 patients from the RENAL trial. We measured the dose and
evolution of DCI during treatment and analyzed its association with major clinical outcomes using multivariable
logistic regression, Cox proportional hazards models, and time adjusted models.
Results: Overall, mean DCI during treatment in ICU was low at only 10.9 ± 9 Kcal/kg/day for non-survivors and
11 ± 9 Kcal/kg/day for survivors. Among patients with a lower DCI (below the median) 334 of 729 (45.8%) had died
at 90-days after randomization compared with 316 of 727 (43.3%) patients with a higher DCI (above the median)
(P = 0.34). On multivariable logistic regression analysis, mean DCI carried an odds ratio of 0.95 (95% confidence
interval (CI): 0.91-1.00; P = 0.06) per 100 Kcal increase for 90-day mortality. DCI was not associated with significant
differences in renal replacement (RRT) free days, mechanical ventilation free days, ICU free days and hospital free days.
These findings remained essentially unaltered after time adjusted analysis and Cox proportional hazards modeling.
Conclusions: In the RENAL study, mean DCI was low. Within the limits of such low caloric intake, greater DCI was not
associated with improved clinical outcomes.
Trial registration: ClinicalTrials.gov number, NCT00221013Introduction
Achieving an adequate daily calorie intake (DCI) is widely
considered beneficial in critically ill patients in general and
in particular in patients with acute kidney injury (AKI) [1].
Guidelines recommend the early administration of enteral
nutrition whenever possible to achieve an energy intake
of 25 to 35 Kcal/day and consideration of parenteral
nutrition when enteral nutrition cannot achieve such
calorie intake goals [2-4]. However, despite the above* Correspondence: rinaldo.bellomo@austin.org.au
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unless otherwise stated.guidelines, there is also concern that the administration
of energy at such levels in critically ill patients may not
be advantageous [5]. Some investigators have shown
that low calorie nutrition alone may be sufficient [6] or
even desirable [7].
In severe AKI patients who require continuous renal
replacement therapy (CRRT), there are very limited data
on current practice or on the association between energy
intake and patient-centered outcomes. In this setting, all
studies are almost 20 years old, single center in design,
small in size and with replacement fluid or dialysate fluids
rich in glucose and/or lactate [8-11]. Such practices are
not relevant to modern CRRT [12-14]. Finally, the impactl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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sial as it may both lead to decreased energy expenditure
through cooling; increased loss of energy as patients seek
to maintain body temperature in the presence of an extra-
corporeal circuit, or nutrient loss across the filter [15,16].
The Randomized Evaluation of Normal vs. Augmented
Level of Replacement Therapy (RENAL) study [17-20],
offers a unique opportunity to explore the association
between DCI and outcome because of its size and the
availability of detailed DCI data. Accordingly, we conducted
a secondary analysis of the RENAL study findings to
describe current DCI practice in such patients and study
the association between DCI and clinical outcomes.
Methods
The RENAL study was a multicenter, prospective, ran-
domized trial of two levels of intensity of CRRT in 1,508
critically ill patients with AKI conducted in 35 ICUs in
Australia and New Zealand [17,21]. The Human Research
Ethics Committees of the University of Sydney and all
participating institutions approved the study (Additional
file 1 provides a list of the institutional review boards
that approved the study). Written informed consent was
obtained from patients or their person responsible.
The methodological details of the RENAL study were
recently reported [17]. In brief, patients were eligible for
enrollment if they were critically ill adults who had AKI,
were deemed by the treating clinician to require RRT
and fulfilled predefined criteria. Eligible patients were
randomly assigned to continuous veno-venous hemodia-
filtration (CVVHDF) with effluent flow at 40 ml/Kg/hr
(higher intensity) or 25 ml/Kg/hr (lower intensity). Study
treatment was discontinued on death, discharge from
ICU, or recovery of renal function. The primary study
end point was death from any cause by day 90.
Daily calorie intake
The study did not prescribe any nutritional intake protocol.
Nutritional therapy was left to the discretion of attending
clinicians. In all patients, DCI was calculated as the sum of
all calories administered each day with the exclusion of
protein nitrogen. For each patient a mean was calculated
during the study period using the DCI value for each day.
For the purpose of the study, calorie intake included: a) all
glucose given parenterally as part of either drug infusions
in 5% glucose or maintenance fluid containing glucose; b)
any parenteral nutrition; c) all lipids administered as part
of parenteral nutritional solutions, and d) all carbohydrate
or lipid-derived calories administered as enteral nutritional
solutions. Propofol intake was taken into account. Accord-
ing to the study protocol, DCI data were obtained until the
first occurrence of either death, or ICU discharge or the
completion of 28 days from study randomization (study
treatment period).Statistical analysis
Continuous variables were expressed as means with SD
for normally distributed variables and as median and IQR
for non-normally distributed variables. Comparisons were
made using the Student t-test or the Mann-Whitney test
where appropriate. We divided patients into two groups
according to mean DCI calculated for each patient during
the study period, low DCI when the individual mean DCI
was lower than the median value for the study population
and high DCI when individual mean DCI was greater than
the median value. Patients with lower and higher DCI
were compared by univariate analysis. We then compared
the DCI of survivors and non-survivors for DCI and the
progressive change over time in DCI. Mean DCI-related
variables (dichotomized and continuous) were then as-
sessed for their independent relationship with survival by
multivariable logistic regression analysis with adjustment
for co-linearity and with adjustment for the following vari-
ables: treatment group, acute physiology and chronic
health evaluation (APACHE) III score, APACHE III diag-
nostic groups, daily use of CRRT, age, time from ICU to
randomization, presence of sepsis, sequential organ failure
assessment (SOFA) respiratory score, SOFA coagulation
score, SOFA liver score, SOFA cardiovascular score, SOFA
renal score, presence of non-renal organ failure, inter-
national normalized ratio (INR) for prothrombin time,
activated partial thromboplastin time (APPT), platelet
count, serum creatinine, arterial partial pressure of oxygen/
inspired oxygen fraction (PaO2/FiO2) ratio, tension of
carbon dioxide in arterial blood (PaCO2), pH, glucose,
albumin, hemoglobin, use of mechanical ventilation, mean
daily fluid balance, and clinical diagnosis of significant
edema at randomization.
Multivariable linear regression analysis was similarly
used to assess the relationship between individual mean
DCI and mechanical ventilation-free days; RRT-free days;
ICU-free days and hospital-free days at 90 days, as the
dependent variables. Unadjusted analysis of time to death
within 90 days of randomization used the Kaplan-Meier
product limit estimates and compared survival curves
using the log-rank test. To assess whether post-ICU treat-
ment might have affected our findings, we also estimated
the relationship between DCI and mortality censored at
28 days or ICU discharge. To test the robustness of any
association between mortality and DCI, additional models
were applied to data analysis. Such multivariable models
included time-adjusted modeling with a cut off of 96 hrs
(to exclude patients who died before full nutrition was
achieved) and Cox proportional hazards modeling ap-
plying the same adjustments for variables included in
the logistic regression model. A two-sided P-value <0.05
was taken to indicate statistical significance. Statistical
analyses were performed and independently checked with
the use of SAS software, version 9.1.
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Of the 1,508 patients enrolled in the RENAL study,
complete DCI data were available for 1,456 (96.6%). The
characteristics of study patients according to whether
they received low or high amounts of DCI are compared
in Table 1 and are significantly different between the
two groups.
Among patients with a low mean DCI, 334 of 729
(45.8%) had died 90 days after randomization, compared
with 316 of 727 (43.3%) patients who received a mean
DCI above the median value (P = 0.34). Moreover, mean
DCI was 867 Kcal/day, with a value among non-survivors
of 847 Kcal/day (10.9 Kcal/Kg/day) compared with 883
Kcal/day (11.0 Kcal/Kg/day) among survivors (P = 0.32)
(Table 2). Mean calorie to protein ratio was 24.9, with a
value of among non-survivors of 25.2 compared with 24.7
among survivors (P = 0.39).
Overall, 874 patients received enteral nutrition only
on 8,334 study days (69.1%), and 382 patients received
parenteral nutrition only for a total of 1,667 (13.8%)
study days and 200 patients received a combination of
enteral and parenteral nutrition for a total of 2,055
(17.1%) study days. The daily DCI for survivors and
non-survivors for the first 14 days of observation is dis-
played in Figure 1. DCI in both groups tended to increase
over time reaching a near plateau after approximately
96 hrs. The unadjusted time-to event analysis is shown in
Figure 2a for all patients and in Figure 2b after removing
patients who died in the first 96 hrs.
On multivariable logistic regression analysis, only a few
variables remained independently associated with 90-day
mortality (Table 3). Importantly, increased daily DCI during
study treatment was not independently associated with
decreased mortality. On multivariable linear regression ana-
lysis, DCI also showed no association with decreased RRT-
free days at day 90 after randomization. When the outcome
was survival at 28 days or ICU discharge, there was still no
association between DCI above the median value and out-
come (odds ratio (OR) 1.02; 95% CI 0.61, 1.71; P = 0.93).
When a DCI >25 Kcal/Kg/day was used to indicate ad-
equate calorie intake, no significant association was found
(OR 0.93; 95% CI 0.47, 1.72; P = 0.75). Similar findings were
seen when the outcomes of interest were RRT-free days,
ICU-free days or hospital-free days (Table 4a, b, c).
The association of DCI with outcomes was also tested
by means of additional time-adjusted modeling (1,183
patients were still alive after 96 hrs) and Cox proportional
hazards modeling. Both modeling approaches confirmed
the main study findings (see Additional file 2).
Discussion
Statement of key findings
We used data from a multicenter, randomized, con-
trolled trial of the intensity of CRRT in critically illpatients with AKI to describe current calorie administra-
tion practice and to assess the association between DCI
and clinical outcomes. We found that overall mean DCI
was low at approximately 11 Kcal/Kg/day. In addition,
we found that patients with a high DCI (above the
median) had similar mortality to patients with a low
DCI (below the median). Finally, non-survivors had a
similar DCI to survivors. When we estimated the inde-
pendent association between DCI and outcome at day
90, a high DCI was not independently associated with
a significant decrease in the OR for 90-day mortality. To
further test the robustness of this finding we performed
additional time-adjusted analyses and Cox proportional
hazards modeling. These analyses found no independent
association between DCI and 90-day mortality or other
clinical outcomes.
Comparison with previous studies
No other studies have reported current calorie delivery
practice in patients with AKI. In general critically ill pa-
tients however, a recent multicenter observational study
in 167 ICU’s found that mean DCI was 14 Kcal/Kg/day
[22], a value only slightly above that found in our study.
In a recent multicenter trial of intensive insulin therapy
in critically ill patients [23], mean DCI was approximately
11 Kcal/Kg/day, a value identical to that delivered to our
patients. Thus, current calorie administration practice
in Australia and New Zealand (ANZ) is similar to current
ICU practice worldwide. In the multicenter observational
study of nutrition in general ICU patients cited above,
greater mean DCI appeared associated with improved
survival. However, no adjustment was made for the
competing risk of death [24]. Such bias can be clearly
demonstrated in critically ill patients [23,25] where mean
DCI increases with time. Thus, patients who die early
inevitably receive fewer calories. This pattern creates
an artificially inflated chance of an apparent association
between greater mean DCI and survival.
Authors [26] and guidelines [3,4,27] continue to rec-
ommend a DCI of at least 25 to 35 Kcal/Kg/day in
AKI patients, yet, the evidence supporting such rec-
ommendations is weak and based on small to very
small single-center studies with physiological outcomes
only. Moreover, although such recommendations appear
reasonable from a physiological and energy expenditure
grounds [28-30], no randomized controlled trials (RCTs)
exist to compare, for example 10 Kcal/Kg/day (current
practice) to 30 Kcal/Kg/day (recommended practice) of
energy intake in AKI patients. In support of the need
for RCTs, recent investigations have found that permis-
sive underfeeding, trophic feeding or delayed parenteral
feeding may be equivalent or perhaps even superior to
currently recommended approaches [5-7,25].
Table 1 Comparison of baseline characteristics for patient with low (below median) and high (above median) mean
daily calorie intake (DCI)
Baseline characteristics Low DCI, n = 729 High DCI, n = 728 P-value
Age 65.4 (14.8) 64.7 (14.9) 0.022
Male sex 457 (62.7%) 484/728 (66.5%) 0.129
eGFR 53.0 (30.9) 60.1 (30.7) 0.001
Mechanical ventilation 437 (59.9%) 639 (87.8%) <0.001
Severe sepsis at baseline 307 (42.1%) 412 (56.6%) <0.001
APACHE III score 103.4 (25.8) 101.5 (25.6) 0.163
SOFA cardiovascular 2.7 (1.6) 3.0 (1.4) <0.001
SOFA respiration (score) 2.5 (1.1) 3.0 (0.7) <0.001
SOFA coagulation (score) 0.8 (1.1) 1.1 (1.2) <0.001
SOFA liver (score) 0.9 (1.2) 1.0 (1.1) 0.300
Weight 79.9 (12.8) 81.4 (13.0) 0.029
Source of admission
Accident and emergency department 187/686 (27.3%) 161/679 (23.7%) 0.003
Hospital floor/ward 215/686 (31.3%) 172/679 (25.3%)
Transfer from another ICU 43/686 (6.3%) 66/679 (9.7%)
Transfer from another hospital 65/686 (9.5%) 89/679 (16.6%)
Operating room/recovery after emergency surgery 91/686 (13.3%) 113/679 (11.5%)
Operating room/recovery after elective surgery 85/686 (12.4%) 78/679 (14.1%)
Non-operative admission diagnosis
Cardiovascular 245/536 (45.7%) 287/510 (56/3%) <0.001
Genitourinary 177/536 (33.0%) 52/510 (10.2%)
Gastrointestinal 39/536 (7.3%) 36/510 (7.1%)
Hematology 10/536 (1.9%) 12/510 (2.4%)
Metabolic/endocrine 14/536 (2.6%) 11/510 (2.2%)
Neurologic 4/536 (0.7%) 6/511 (1.2%)
Respiratory 43/536 (8.0%) 103/511 (20.2%)
Transplant 4/536 (0.7%) 1/511 (0.2%)
Trauma 0/536 (0.0%) 2/511 (0.4%)
Operative admission diagnosis
Cardiovascular 131/193 (67.9%) 137/218 (62.8%) 0.256
Genitourinary 3/193 (1.6%) 1/218 (0.5%)
Gastrointestinal 39/193 (20.2%) 57/218 (26.1%)
Neurologic 3/193 (1.6%) 4/218 (1.8%)
Respiratory 3/193 (1.6%) 5/218 (2.3%)
Transplant 7/193 (3.6%) 2/218 (0.9%)
Trauma 7/193 (3.6%) 12/218 (5.5%)
Plasma urea (mmol/L) 23.7 (13.8) 23.3 (11.7) 0.542
Creatinine at randomization (μmol/L) 369 (231) 300 (142) <0.001
pH 7.2 (0.1) 7.3 (0.1) <0.001
Bicarbonate (mmol/L) 17.1 (5.8) 19.5 (5.6) <0.001
Base excess (mEql/L) −9.7 (6.9) −6.9 (6.7) <0.001
Continuous variables expressed as mean with standard deviation in brackets. Nominal variables expressed as number with percentage in brackets. SOFA, sequential
organ failure score; RRT, renal replacement therapy; MV, mechanical ventilation; APACHE, acute physiology and chronic health evaluation; eGFR, estimated glomerular
filtration rate.
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Table 2 Daily calorie intake (DCI) according to survival
status at 90 days after randomization
Baseline characteristics Non-survivors,
n = 654
Survivors,
n = 810
P-value
Mean DCI during study
Number 649 807 0.3185
Mean calories (SD) 846.7 (681) 883.3 (709)
Q1 Q2 Q3 148.0 839.7 1412 90.0 905.8 1447
Missing 5 3
Weight-adjusted mean
DCI during study
Number 649 807 0.8086
Mean calories/kg (SD) 10.9 (9.0) 11.0 (9.0)
Q1 Q2 Q3 1.7 10.4 17.4 1.1 11.2 17.6
Missing 5 3
Refers to index admission to a maximum of 28 days (trial treatment);
weight-adjusted DCI/patient weight in Kg; Q, quartile.
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These findings from the RENAL study provide the first
data on current nutritional practice in patients with severe
AKI. They also provide novel information on the relation-
ship between mean DCI and outcome. Such information
was collected as part of large multicenter study with
independent data verification and negligible missing data.
They also provide such information in the setting of essen-
tially exclusive CRRT use. This difference is important be-
cause intermittent hemodialysis (IHD) has been shown to
limit the ability to control volume status and uremia in
critically ill patients with AKI [29,31], thereby potentially
impeding full nutritional intake. On the other hand, withFigure 1 Graphic representation of mean daily caloric intake (DCI) ov
to survival status at 90 days.CRRT, volume control and full nutritional therapy are free
of the limitations imposed by IHD. Thus, given that fluid
accumulation is not a problem, mean DCI in this setting
can be logically taken to reflect therapeutic choices rather
than technical limitations.
Our study demonstrates that mean DCI was well below
guideline-based targets in patients receiving CRRT. By
assessing, for the first time, its relationship with patient
outcomes in the setting of prospective and detailed data
collection within a large cohort of patients treated with
CRRT, our study also provides evidence that within the
range of mean DCI provided in this study, there was no
robust independent association between greater mean
DCI and favorable outcome, including 90-day mortality
and other patient-centered outcomes such as mechanical
ventilation, ICU- and hospital-free days. In fact, after early
deaths were excluded, patients with a DCI above the
median were more likely to die. This surprising finding is
possibly due to the confounding effect of time (DCI in-
creases with time and patients who are still in ICU as time
goes by have failed to improve and are thus more likely to
die) but, nonetheless, highlights the lack of a robust and
unchanging relationship with DCI which, if present, may be
expected to overcome the effect of confounding.
Our findings may provoke further debate on whether
caloric intake is an important determinant of outcome;
whether caloric targets as set by current guidelines are
justified and whether more restrictive approaches may be
acceptable or even desirable. The mechanism responsible
for the failure of enhanced nutritional intake to change
patient outcome may be complex and may depend on
both anabolic resistance [32] and in AKI patients, oner the first 2 weeks of observation after randomization according
Figure 2 Kaplan-Meier plots before and after excluding early deaths. (a) Kaplan-Meier graph of survival plots from randomization to day 90
stratified by the delivery of lower (below median) or higher (above median) daily calorie intake (DCI) during the index ICU admission. No P-values
are provided as the plot is not adjusted for confounders and is shown to emphasize the reversal of the curve (see Figure 2b) once early deaths
are excluded. (b) Kaplan-Meier graph of survival plots from randomization to day 90 stratified by the delivery of lower (below median) or higher
(above median) DCI during the index ICU admission, after exclusion of patients who died in the first 96 hrs. No P-values are provided as the plot
is not adjusted for confounders and is shown to emphasize the reversal of the curves (see Figure 2a) once early deaths are excluded.
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condition [33]. Recent data from randomized controlled
trials of nutrition in critically ill patients [5-7,25] also
suggest that a more conservative approach to caloric
delivery may, at the very least, be safe. Given that
severe AKI is relatively common in critically ill patients
and given such therapeutic uncertainty, RCTs are urgently
needed.Study strengths and limitations
This study reports observational findings from a large
multicenter randomized controlled study of CRRT for
AKI. The data were prospectively collected with specific
attention to mean DCI and independently monitored for
accuracy, and were free of selection bias. As such, they
provide the most comprehensive description of mean DCI
during CRRT and of its association with outcome to date.
Table 3 Multivariate logistic regression for 90-day mortality
Variable name Effect (discrete variable) Odds ratio CI (95%) P-value
Median daily calorie intake during ICU admission High versus low 1.079 0.55 2.13 0.8275
Mean daily calorie intake during ICU admission (per 100 Kcal change) 0.953 0.91 1.00 0.0636
Mean fluid balance (input-output) (litre) 2.016 1.61 2.53 <.0001
Patient's age 1.037 1.03 1.05 <.0001
Patient's weight (Kg) 0.989 0.98 1.00 0.0394
Time from ICU admission to randomization (days) 1.002 1.00 1.00 0.0047
SOFA liver (score) Failure versus normal 3.384 1.55 7.38 0.0022
International normalized ratio 1.200 1.03 1.39 0.0172
Hemoglobin (g/L) 0.992 0.98 1.00 0.0353
Albumin (g/L) 0.977 0.96 1.00 0.0300
PaCO2 (mm/Hg) 1.016 1.00 1.03 0.0249
Daily calorie intake and all variables with P <0.05 presented; APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment;
PaCO2, tension of carbon dioxide in arterial blood.
Table 4 Multivariable linear regression for secondary outcomes*
Variable name Estimate Standard error P-value
a. Multivariable linear regression for RRT-free days
Intercept −40.32510 33.71933 0.2323
Mean daily calorie intake during ICU admission 0.00189 0.00171 0.2695
Median daily calorie intake during ICU admission −1.09792 2.61145 0.6744
Positive mean fluid balance −4.09805 0.87492 <.0001
Treatment −1.97170 0.85163 0.0210
Time from ICU admission to randomization (in days) −0.01644 0.00469 0.0005
SOFA liver (score) −1.63540 0.44579 0.0003
APPT −0.05581 0.02105 0.0083
pH 8.45062 4.27094 0.0484
b. Multivariate linear regression of ICU-free days
Intercept −221.76773 281.51940 0.4313
Mean daily calorie intake during ICU admission 0.00468 0.00649 0.4714
Median daily calorie intake during ICU admission 2.89089 8.90361 0.7456
Positive mean fluid balance −19.69578 3.36383 <.0001
Positive ventilation: no = reference group −13.45268 5.58339 0.0165
Patient's weight (Kg) 0.45320 0.13896 0.0012
Time from ICU admission to randomization (days) −0.03736 0.01756 0.0340
Last creatinine concentration 0.11279 0.04434 0.0114
c. Multivariate linear regression of hospital-free days
Intercept 25.05875 258.60573 0.9229
Mean daily calorie intake during ICU admission −0.00349 0.00601 0.5625
Median daily calorie intake during ICU admission 2.11260 8.32222 0.7997
Positive mean fluid balance −16.17529 3.08521 <.0001
Patient's weight (Kg) 0.29499 0.12933 0.0231
Last serum urea concentration −3.72244 1.85441 0.0454
Last creatinine concentration 0.09767 0.04131 0.0185
Glucose (mmol/L) 1.09456 0.50830 0.0319
*Only DCI related variable and significant variables reported. SOFA, sequential organ failure assessment; activated partial thromboplastin time.
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data with primary outcome at 90 days. This approach
avoided informative censoring of competing events and
90-day mortality is free from ascertainment bias unlike
other more subjective primary endpoints (for example,
infections) sometimes used in the literature. In addition,
all patients had prospectively collected demographic,
illness severity and biochemical data at baseline that
could be used in multivariable models to adjust for the
effect of confounders. The statistical analysis was extensive
and involved assessment of the time-bias, a factor that can
easily confound the association between nutritional intake
and outcome.
On the other hand, the range of DCI was small, thus,
despite being the largest study to date, we may have insuf-
ficient power to detect an independent association due to
the limited number of patients with a DCI >25 Kcal/Kg/
day. We could not account for unrecorded variables (such
as gastrointestinal dysfunction) that may have affected
DCI. We do not have information to explain why caloric
intake was low and why it took an average of approxi-
mately 4 days for nutrition to reach a plateau. Moreover,
data were only available from the time of randomization
and did not provide information on mean DCI prior to
treatment or after 28 days or ICU discharge. However,
the fact that in the RENAL trial the time between ICU
admission and randomization was <2 days and the mean
duration of study time was approximately 13 days all
suggest that the pre-randomization period was unlikely
to materially affect the study findings. In addition, the
sensitivity analysis showing that the 28-day outcome
assessment leads to the same findings as the 90-day
outcome assessment provides evidence that interventions
after day 28 or ICU discharge are unlikely to have influ-
enced our observations. We did not collect information
on the daily dose of propofol infusion. Thus, we cannot
quantify its caloric contribution. We do not have infor-
mation on insulin intake and glucose control. However,
glucose management in ANZ has remained steady over
the last decade with a mean glucose value of approximately
8 mmol/L [34]. We do not have information on the caloric
input derived from normal oral intake. However, such
intake was uncommon in these critically ill patients
while in ICU and is difficult to quantify. We consider
that its overall contribution was negligible. Finally, we
do not report on the calories delivered to patients by
means of CRRT because its estimate is problematic. All
CRRT was performed in all patients with bicarbonate
fluids containing 1 g of glucose per liter (5.55 mmol/L)
thus potentially delivering 200 to 300 Kcal/day. However,
half of the fluid was administered as dialysate, where
glucose movement into the patient’s blood stream would
be dependent on the glucose gradient and dynamically
influenced by the patient’s glucose level. Thus, in hypergly-cemic patients, CRRT may have resulted in glucose and
caloric loss in hyperglycemic patients and in caloric gain in
normoglycemic patients. Such losses and gains would have
varied over time according to glycemia, filter function,
down time and CRRT intensity making correct estimates
essentially impossible.
Conclusions
In the RENAL study, overall mean DCI was low. However,
patients with a lower mean DCI had similar mortality than
those with a higher DCI and non-survivors had a similar
mean DCI to survivors. After correction for multiple
confounding variables and the application of different
statistical modeling techniques, a lower mean DCI was not
robustly independently associated with increased risk of
death at 90 days, or with other major clinical outcomes.
Higher-level evidence is needed to better define the opti-
mal DCI target in this important subgroup of patients.
Key messages
 In the largest multicenter study of AKI treatment
with CRRT to date, the average mean DCI was low
at 11 KCal/Kg/day
 In severe AKI patients stable calorie intake was only
achieved at 4 to 5 days after randomization
 Patients with a low or high mean DCI had similar
mortality rates
 Mean DCI was similar among survivors and
non-survivors
 After adjustment for multiple confounders,
increased daily DCI during study treatment
was not independently associated with decreased
mortality, decreased RRT-free days ICU-free days
or hospital-free days
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Additional file 2: Table S1. Multivariate logistic regression model for
day-90 mortality including only patients who survived >96 hrs. Table S2
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regression of mechanical ventilation-free days including only patients who
survived >96 hrs. Table S4 Multivariate linear regression of ICU-free days
including only patients who survived >96 hrs. Table S5 Multivariate linear
regression of hospital-free days including only patients who survived >96 hrs.
Table S6 Cox regression model for death at day 90.
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